Monitoring the bioavailability of FEIBA with a thrombin generation assay

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 11, 2003, Pages 2374-2380

  Varadi K ^a   Negrier, C ^b   Berntorp, E ^c   Astermark, J ^c   Bordet, J C ^a   Morfini, M ^d   Linari, S ^d   Schwarz, H P ^a   Turecek, P L ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

FEIBA; Hemophilia a inhibitor; Pharmacokinetics; Thrombin generation

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALLOANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; THROMBIN;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; BIOSYNTHESIS; BLOOD; BLOOD CLOTTING TEST; DRUG MONITORING; DRUG SCREENING; FEMALE; HEMOPHILIA A; HUMAN; IMMUNOLOGY; MALE; METHODOLOGY; PHARMACOKINETICS;

ADULT; AGED; BIOLOGICAL AVAILABILITY; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; DRUG EVALUATION; DRUG MONITORING; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; ISOANTIBODIES; MALE; PHARMACOKINETICS; THROMBIN;

EID: 3242737794     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00450.x     Document Type: Article

References (19)

1. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors: benefits and limitations. Semin Hematol 1994; 31 (2 Suppl. 4): 49-52.
2. Roberts HR. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia. Vox Sang 1999; 77 (Suppl. 1): 38-41.
3. Turecek PL, Varadi K, Gritsch H, Auer W, Pichler L, Eder G, Schwarz HP. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999; 77 (Suppl. 1): 72-9.
4. ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor Vila in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-12.
5. Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechan ism of activated factor Vila independent of tissue factor. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S15-S20.
6. Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17.
7. Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-8.
8. Sultan Y, Loyer F. In vitro evaluation of factor VHI-bypassing activity of activated prothrombin complex concentrate, prothrombin complex con centrate, and factor Vila in the plasma of patients with factor VIII inhibitors: thrombin generation test in the presence of collagen-acti vated platelets. J Lab Clin Med 1993; 121: 444-52.
9. Schwarz HP, Rengs H, Elsinger F. An assay for the bioavailability of FEIBA 1989. Kyoto Satellite Symposia at the Xllth Congress of ISTH, 1989.
10. Madlener K, Gissel B, Brackmann H, Potzsch B. The Endogenous Thrombin Generation Potential (ETP) is an accurate and rapid monitor ing method for recombinant factor Vila. Ann Hematol 2000; 79 (Suppl. I): A46.
11. Varadi K, Siekmann J, Turecek PL, Schwarz HP, Marder VJ. Phospho- lipid-bound tissue factor modulates both thrombin generation and APC-mediated factor Va inactivation. Thromb Haemost 1999; 82: 1673-9.
12. Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, Van Eys J. A more uniform measurement of factor VIII inhibitors. Thromb Diathes Haemorrh 1975; 34: 869-72.
13. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII adminis tered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
14. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-50.
15. Hemker HC, Giesen PLA, Ramjee M, Wagenvoord R, Beguin S. The Thrombogram: monitoring thrombin generation in platelet rich plasma. Thromb Haemost 2000; 83: 589-91.
16. Houbouyan L, Padilla A, Gray E, Longstaff C, Barrowcliffe TW. Inhibition of thrombin generation by heparin and LMW heparins: a comparison of chromogenic and clotting methods. Blood Coagul Fi brinolysis 1996; 7: 24-30.
17. AI Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, Beguin S, Coenraad Hemker H. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-82.
18. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
19. Hilgartner M, Aledort L, Andes A, Gill J, and the members of the FEIBA Study Group. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion 1990; 30: 626-30.